查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1709467

呼吸道合胞病毒治療市場，依治療類型、劑型、年齡層、配銷通路、國家和地區 - 2025 年至 2032 年全球產業分析、市場規模、市場佔有率和預測

Respiratory Syncytial Virus Therapeutics Market, By Treatment Type, By Dosage Form, By Age Group, By Distribution Channel, By Country, and By Region - Global Industry Analysis, Market Size, Market Share & Forecast from 2025-2032
出版日期: | 出版商: AnalystView Market Insights | 英文 299 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

報告重點

2024 年呼吸道合胞病毒治療市場規模價值 15.9032 億美元，2025 年至 2032 年的複合年成長率為 15.50%。

診斷技術的進步有助於早期發現和及時介入。北美和歐洲憑藉其強大的醫療保健基礎設施和較高的認知度佔據主導地位，而新興經濟體則顯示出日益成長的採用率。生物技術公司和醫療保健組織之間的合作進一步支持了市場的成長。預計成本效益療法的引入將提高全球範圍內的可及性，確保更好地管理疾病。

呼吸道合胞病毒治療市場-市場動態

擴大採用長效單株抗體來保護嬰兒免受呼吸道合胞病毒感染。

長效單株抗體在嬰兒呼吸道合胞病毒防護中的應用日益增多，這是呼吸道合胞病毒治療市場的主要驅動力。傳統的單株抗體，例如帕利珠單抗，需要每月服用一次，限制了其可及性和依從性。然而，像 Nirsevimab 這樣的較新的長效抗體只需單劑量就能提供更長的保護，使其更加方便和具有成本效益。政府和醫療保健組織正在積極推薦高風險嬰兒接受這些療法，以減少與呼吸道合胞病毒相關的住院。新生兒和早產兒呼吸道合胞病毒感染負擔沉重，導致免疫接種計畫擴大。此外，長效單株抗體的監管批准和資金投入正在增加其在已開發市場和新興市場的可用性。隨著這些療法越來越融入常規嬰兒護理，預計它們將顯著推動市場成長。

呼吸道合胞病毒治療市場—關鍵見解

根據我們的研究分析師的分析，預計全球市場在預測期內（2025-2032 年）的年複合成長率約為 15.50%

根據治療類型細分，預計單株抗體將在 2024 年佔據最大市場佔有率

根據劑型細分，注射劑是 2024 年的主要劑型

根據年齡層細分，嬰幼兒是 2024 年領先的年齡層

根據配銷通路細分，醫院和診所是 2024 年領先的配銷通路

按地區分類，北美是 2024 年最大的收入來源

呼吸道合胞病毒治療市場-區隔分析：

全球呼吸道合胞病毒治療市場根據治療類型、劑型、年齡層、配銷通路和地區進行細分。

根據治療類型，市場分為三類：抗病毒藥物、單株抗體和疫苗。單株抗體在呼吸道合胞病毒 (RSV) 治療市場中佔據主導地位，因為它們能有效預防嚴重的 RSV 感染，尤其是在嬰兒和老年人等高風險族群中。帕利珠單抗已被廣泛使用多年，而最近批准的 Nirsevimab 等長效單株抗體進一步加強了這一領域。這些治療提供了被動免疫，減少了與呼吸道合胞病毒相關的住院和併發症。 RSV 感染負擔的持續加重，以及政府建議弱勢群體使用單株抗體，刺激了需求。製藥公司繼續投資開發具有更高療效和更長作用時間的下一代單株抗體。此外，這些療法的高成本對市場收入貢獻巨大。由於強大的醫療保健基礎設施和報銷政策，北美和歐洲在採用方面處於領先地位。隨著新的抗體製劑獲得監管部門的批准，預計該領域將在 RSV 治療市場中保持主導地位。

根據劑型，市場分為三類：口服、注射和吸入。由於單株抗體和疫苗的廣泛使用（主要透過注射給藥），注射劑在呼吸道合胞病毒 (RSV) 治療市場中佔據主導地位。帕利珠單抗和尼爾塞維單抗等單株抗體以及新批准的老年人呼吸道合胞病毒疫苗都依靠注射劑型進行有效傳遞。此途徑確保了精確的劑量、快速的吸收和長期的保護，使其成為高風險族群的首選。嬰兒和老年人嚴重呼吸道合胞病毒感染的發生率不斷上升，導致注射治療的應用增加。此外，政府免疫計劃和醫院規程都支持注射呼吸道合胞病毒療法，進一步推動了這一領域的發展。由於強大的醫療保健基礎設施和較高的疫苗覆蓋率，北美和歐洲在注射呼吸道合胞病毒療法方面處於領先地位。隨著更多長效單株抗體和呼吸道合胞病毒疫苗獲得批准，注射劑市場預計將保持主導地位。

呼吸道合胞病毒治療市場-地理洞察

由於知名度高、醫療保健基礎設施強大以及單株抗體和疫苗的廣泛採用，北美在呼吸道合胞病毒 (RSV) 治療市場佔據主導地位。美國在該地區處於領先地位，擁有政府支持的免疫計劃和監管部門批准的先進呼吸道合胞病毒療法，如 Nirsevimab 和老年人呼吸道合胞病毒疫苗。嬰兒和老年族群中因呼吸道合胞病毒相關疾病住院的人數不斷增加，推動了對有效治療的需求。此外，各大製藥公司正在投資研發，以推出下一代單株抗體。優惠的報銷政策和高額的醫療保健支出進一步支持了該地區的市場成長。

美國憑藉其先進的醫療保健基礎設施、高度的疾病意識和強力的政府支持，佔據呼吸道合胞病毒 (RSV) 治療市場的最大佔有率。美國疾病管制與預防中心 (CDC) 和美國食品藥物管理局 (FDA) 已批准用於老年人的呼吸道合胞病毒疫苗和嬰兒保護的長效單株抗體（如 Nirsevimab），從而推動了該疫苗的廣泛應用。呼吸道合胞病毒相關住院人數不斷增加，尤其是嬰兒和老年人，這增加了對有效治療的需求。政府支持的免疫計劃和報銷政策進一步促進了市場成長。此外，製藥公司正在大力投資研究和臨床試驗，以開發下一代 RSV 療法。該國的高醫療支出和健全的監管框架確保了市場持續擴張。

呼吸道合胞病毒治療市場-競爭格局：

呼吸道合胞病毒 (RSV) 治療市場的競爭格局以密集的研究和開發 (R&D) 努力、策略合作和監管部門批准為特點。領先的製藥公司專注於開發單株抗體、疫苗和抗病毒藥物，以應對日益加重的 RSV 感染負擔。市場由阿斯特捷利康、賽諾菲、輝瑞、葛蘭素史克和 Moderna 主導，這些公司已經推出或正在開發創新的 RSV 療法。

主要參與者正在利用策略合作夥伴關係和收購來擴大其產品組合，例如輝瑞收購 ReViral 以進行 RSV 抗病毒開發。 Nirsevimab 等長效單株抗體和老年人呼吸道合胞病毒疫苗的核准加劇了競爭。公司也專注於臨床試驗、政府合作和定價策略以鞏固其市場地位。隨著對呼吸道合胞病毒預防和治療的需求不斷增加，隨著新進業者和先進的治療解決方案的出現，競爭格局預計將發生變化。

最新動態：

2024 年 2 月，葛蘭素史克公司宣布，美國食品藥物管理局 (FDA) 對其呼吸道合胞病毒 (RSV) 聯合疫苗的適應症擴大至 50 至 59 歲患 RSV 疾病風險較高的人群的申請給予優先審查。

2023年5月，輝瑞表示，美國食品藥物管理局（FDA）核准其二價RSV預融合F（RSVpreF）疫苗ABRYSVO，用於預防60歲以上人口由RSV引起的下呼吸道疾病。這一策略促進了公司的收入成長。

目錄

第 1 章：呼吸道合胞病毒治療市場概述

  • 研究範圍
  • 市場估計年限

第2章：執行摘要

  • 市場片段
    • 呼吸道合胞病毒治療市場片段（依治療類型）
    • 呼吸道合胞病毒治療市場（依劑型分類）
    • 呼吸道合胞病毒治療市場按年齡層細分
    • 呼吸道合胞病毒治療市場片段（依配銷通路）
    • 呼吸道合胞病毒治療市場（依國家/地區）
    • 呼吸道合胞病毒治療市場（按地區）
  • 競爭洞察

第3章：呼吸道合胞病毒治療關鍵市場趨勢

  • 呼吸道合胞病毒治療市場促進因素
    • 市場促進因素的影響分析
  • 呼吸道合胞病毒治療市場限制
    • 市場限制的影響分析
  • 呼吸道合胞病毒治療市場機會
  • 呼吸道合胞病毒治療市場未來趨勢

第4章：呼吸道合胞病毒治療產業研究

  • PEST分析
  • 波特五力分析
  • 成長前景圖
  • 規範架構分析

第5章：呼吸道合胞病毒治療市場：地緣政治緊張局勢升級的影響

  • COVID-19 疫情的影響
  • 俄烏戰爭的影響
  • 中東衝突的影響

第6章：呼吸道合胞病毒治療市場格局

  • 2024年呼吸道合胞病毒治療市佔分析
  • 按主要製造商分類的細分數據
    • 成熟玩家分析
    • 新興企業分析

第7章：呼吸道合胞病毒治療市場－依治療類型

  • 概述
    • 按治療類型分類的細分市場佔有率分析
    • 抗病毒藥物
    • 單株抗體
    • 疫苗

第8章：呼吸道合胞病毒治療市場－按劑型

  • 概述
    • 按劑型分類的細分市場佔有率分析
    • 口服
    • 注射劑
    • 吸入

第9章：呼吸道合胞病毒治療市場－依年齡層

  • 概述
    • 按年齡層別分類的細分佔有率分析
    • 嬰幼兒
    • 成年人
    • 老年人（65歲以上）

第 10 章：呼吸道合胞病毒治療市場 - 按配銷通路

  • 概述
    • 按配銷通路分類的細分市場佔有率分析
    • 醫院和診所
    • 零售藥局
    • 網路藥局

第 11 章：呼吸道合胞病毒治療市場-按地區

  • 介紹
    • 按地區分類的細分市場佔有率分析
  • 北美洲
    • 概述
    • 北美呼吸道合胞病毒治療主要製造商
    • 北美市場規模及預測（按國家/地區）
    • 北美市場規模和預測，按治療類型
    • 北美市場規模及預測（按劑型）
    • 北美市場規模及預測（按年齡層）
    • 北美市場規模及預測（按配銷通路）
    • 美國
    • 加拿大
  • 歐洲
    • 概述
    • 歐洲呼吸道合胞病毒治療主要製造商
    • 歐洲市場規模及預測（按國家/地區）
    • 歐洲市場規模及預測（按治療類型）
    • 歐洲市場規模及預測（按劑型）
    • 歐洲市場規模及預測（依年齡層）
    • 歐洲市場規模及預測（按配銷通路）
    • 德國
    • 英國
    • 法國
    • 義大利
    • 西班牙
    • 荷蘭
    • 瑞典
    • 俄羅斯
    • 波蘭
    • 歐洲其他地區
  • 亞太地區 (APAC)
    • 概述
    • 亞太地區呼吸道合胞病毒治療主要製造商
    • 亞太地區市場規模及預測（依國家）
    • 亞太地區市場規模及預測（依治療類型）
    • 亞太地區市場規模及預測（依劑型分類）
    • 亞太地區市場規模及預測（依年齡層）
    • 亞太地區市場規模及預測（按配銷通路）
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲
    • 印尼
    • 泰國
    • 菲律賓
    • 亞太地區其他地區
  • 拉丁美洲（LATAM）
    • 概述
    • 拉丁美洲呼吸道合胞病毒治療主要製造商
    • 拉丁美洲市場規模及預測（按國家/地區）
    • 拉丁美洲市場規模及預測（按治療類型）
    • 拉丁美洲市場規模及預測（以劑型分類）
    • 拉丁美洲市場規模及預測（按年齡層）
    • 拉丁美洲市場規模及預測（按配銷通路）
    • 巴西
    • 墨西哥
    • 阿根廷
    • 哥倫比亞
    • 拉丁美洲其他地區
  • 中東和非洲（MEA）
    • 概述
    • 中東和非洲呼吸道合胞病毒治療主要製造商
    • MEA 市場規模及預測（依國家/地區）
    • MEA 市場規模及預測（依治療類型）
    • MEA 市場規模及預測（以劑型）
    • MEA 市場規模及預測（依年齡層）
    • MEA 市場規模及預測（依配銷通路）
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 以色列
    • 土耳其
    • 阿爾及利亞
    • 埃及
    • MEA 其餘地區

第 12 章：呼吸道合胞病毒治療產業主要供應商分析

  • 競爭儀錶板
    • Competitive Benchmarking
    • Competitive Positioning
  • 公司簡介
    • AstraZeneca plc
    • Sanofi SA
    • Pfizer Inc.
    • Moderna, Inc.
    • GSK plc
    • Merck & Co., Inc.
    • Johnson & Johnson
    • Novavax, Inc.
    • Bavarian Nordic A/S
    • Enanta Pharmaceuticals, Inc.
    • BioNTech SE
    • Meissa Vaccines, Inc.
    • Codagenix, Inc.
    • Alnylam Pharmaceuticals, Inc.
    • Vaxart, Inc.
    • Icosavax, Inc.

第 13 章：360 度分析師視角

第 14 章：附錄

  • 研究方法
  • 參考
  • 縮寫
  • 免責聲明
  • 聯絡我們
簡介目錄
Product Code: ANV4937

REPORT HIGHLIGHT

Respiratory Syncytial Virus Therapeutics Market size was valued at US$ 1,590.32 Million in 2024, expanding at a CAGR of 15.50% from 2025 to 2032.

The Respiratory Syncytial Virus (RSV) therapeutics market focuses on treatments and preventive solutions for RSV infections, which primarily affect infants, older adults, and immunocompromised individuals. This market includes antiviral drugs, monoclonal antibodies, and vaccines aimed at reducing disease severity and transmission. The increasing prevalence of RSV, along with rising hospitalizations, has driven demand for effective therapies. Governments and pharmaceutical companies are investing in research to develop advanced treatments, including long-acting monoclonal antibodies and novel antivirals. Regulatory approvals for RSV vaccines, especially for high-risk groups, have expanded the market.

Advancements in diagnostic techniques support early detection and timely intervention. North America and Europe dominate due to strong healthcare infrastructure and high awareness while emerging economies show growing adoption. Market growth is further supported by collaborations between biotech firms and healthcare organizations. The introduction of cost-effective therapies is expected to enhance accessibility worldwide, ensuring better disease management.

Respiratory Syncytial Virus Therapeutics Market- Market Dynamics

Increasing adoption of long-acting monoclonal antibodies for infant RSV protection.

The increasing adoption of long-acting monoclonal antibodies for infant RSV protection is a key driver of the RSV therapeutics market. Traditional monoclonal antibodies, such as Palivizumab, required monthly dosing, limiting their accessibility and compliance. However, newer long-acting antibodies like Nirsevimab offer extended protection with a single dose, making them more convenient and cost-effective. Governments and healthcare organizations are actively recommending these therapies for high-risk infants to reduce RSV-related hospitalizations. The high burden of RSV infections in newborns and premature babies has led to expanded immunization programs. Additionally, regulatory approvals and funding for long-acting monoclonal antibodies are increasing their availability in developed and emerging markets. As these therapies become more integrated into routine infant care, they are expected to drive market growth significantly.

Respiratory Syncytial Virus Therapeutics Market- Key Insights

As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 15.50% over the forecast period (2025-2032)

Based on Treatment Type segmentation, monoclonal antibodies were predicted to show maximum market share in the year 2024

Based on Dosage Form segmentation, injectable was the leading Dosage Form in 2024

Based on Age Group segmentation, Infants & Young Children was the leading Age Group in 2024

Based on Distribution Channel segmentation, Hospitals & Clinics was the leading Distribution Channel in 2024

based on region, North America was the leading revenue generator in 2024

Respiratory Syncytial Virus Therapeutics Market- Segmentation Analysis:

The Global Respiratory Syncytial Virus Therapeutics Market is segmented based on Treatment Type, Dosage Form, Age Group, Distribution Channel, and Region.

The market is divided into three categories based on Treatment Type: Antiviral Drugs, Monoclonal Antibodies, and Vaccines. The monoclonal antibodies segment dominates the Respiratory Syncytial Virus (RSV) therapeutics market due to their effectiveness in preventing severe RSV infections, especially in high-risk groups like infants and older adults. Palivizumab has been widely used for years, and the recent approval of long-acting monoclonal antibodies such as Nirsevimab has further strengthened this segment. These treatments provide passive immunity, reducing RSV-related hospitalizations and complications. The increasing burden of RSV infections, along with government recommendations for monoclonal antibody use in vulnerable populations, has fueled demand. Pharmaceutical companies continue to invest in developing next-generation monoclonal antibodies with improved efficacy and longer duration of action. Additionally, the high cost of these therapies contributes significantly to market revenue. North America and Europe lead in adoption due to strong healthcare infrastructure and reimbursement policies. As new antibody formulations receive regulatory approvals, this segment is expected to maintain its dominance in the RSV therapeutics market.

The market is divided into three categories based on Dosage Form: Oral, Injectable, and Inhalation. The injectable segment dominates the Respiratory Syncytial Virus (RSV) therapeutics market due to the widespread use of monoclonal antibodies and vaccines, which are primarily administered via injection. Monoclonal antibodies like Palivizumab and Nirsevimab, as well as newly approved RSV vaccines for older adults, rely on injectable formulations for effective delivery. This route ensures precise dosing, rapid absorption, and prolonged protection, making it the preferred choice for high-risk populations. The rising incidence of severe RSV infections among infants and older adults has led to increased adoption of injectable treatments. Additionally, government immunization programs and hospital protocols favor injectable RSV therapies, further boosting this segment. North America and Europe lead in injectable RSV therapeutics due to strong healthcare infrastructure and high vaccine coverage. As more long-acting monoclonal antibodies and RSV vaccines gain approval, the injectable segment is expected to maintain its dominance.

Respiratory Syncytial Virus Therapeutics Market- Geographical Insights

North America dominates the Respiratory Syncytial Virus (RSV) therapeutics market due to high awareness, strong healthcare infrastructure, and widespread adoption of monoclonal antibodies and vaccines. The U.S. leads the region, with government-backed immunization programs and regulatory approvals for advanced RSV therapies like Nirsevimab and RSV vaccines for older adults. Increasing RSV-related hospitalizations among infants and elderly populations have driven demand for effective treatments. Additionally, major pharmaceutical companies are investing in research and development to introduce next-generation monoclonal antibodies. Favorable reimbursement policies and high healthcare spending further support market growth in the region.

The United States holds the largest share of the Respiratory Syncytial Virus (RSV) therapeutics market due to its advanced healthcare infrastructure, high disease awareness, and strong government support. The CDC and FDA have approved RSV vaccines for older adults and long-acting monoclonal antibodies like Nirsevimab for infant protection, driving widespread adoption. Rising RSV-related hospitalizations, particularly among infants and the elderly, have increased demand for effective treatments. Government-backed immunization programs and reimbursement policies further boost market growth. Additionally, pharmaceutical companies are heavily investing in research and clinical trials to develop next-generation RSV therapeutics. The country's high healthcare spending and robust regulatory framework ensure continued market expansion.

Respiratory Syncytial Virus Therapeutics Market- Competitive Landscape:

The competitive landscape of the Respiratory Syncytial Virus (RSV) therapeutics market is characterized by intense research and development (R&D) efforts, strategic collaborations, and regulatory approvals. Leading pharmaceutical companies focus on developing monoclonal antibodies, vaccines, and antiviral drugs to address the growing burden of RSV infections. The market is dominated by AstraZeneca, Sanofi, Pfizer, GSK, and Moderna, which have introduced or are developing innovative RSV therapeutics.

Key players are leveraging strategic partnerships and acquisitions to expand their product portfolios, as seen in Pfizer's acquisition of ReViral for RSV antiviral development. The approval of long-acting monoclonal antibodies like Nirsevimab and RSV vaccines for older adults has intensified competition. Companies are also focusing on clinical trials, government collaborations, and pricing strategies to strengthen their market position. With increasing demand for RSV prevention and treatment, the competitive landscape is expected to evolve with new entrants and advanced therapeutic solutions.

Recent Developments:

In February 2024, GSK plc announced that the U.S. Food and Drug Administration (FDA) granted priority review for an application to expand the indication of its combined respiratory syncytial virus (RSV) vaccine to individuals aged 50 to 59 at higher risk of RSV illness.

In May 2023, Pfizer Inc. stated that the U.S. Food and Drug Administration (FDA) approved ABRYSVO, its bivalent RSV prefusion F (RSVpreF) vaccine, for preventing lower respiratory tract illness caused by RSV in individuals aged 60 and older. This strategy has contributed to the company's revenue growth.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL RESPIRATORY SYNCYTIAL VIRUS THERAPEUTICS MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

  • AstraZeneca plc
  • Sanofi S.A.
  • Pfizer Inc.
  • Moderna, Inc.
  • GSK plc
  • Merck & Co., Inc.
  • Johnson & Johnson
  • Novavax, Inc.
  • Bavarian Nordic A/S
  • Enanta Pharmaceuticals, Inc.
  • BioNTech SE
  • Meissa Vaccines, Inc.
  • Codagenix, Inc.
  • Alnylam Pharmaceuticals, Inc.
  • Vaxart, Inc.
  • Icosavax, Inc.

GLOBAL RESPIRATORY SYNCYTIAL VIRUS THERAPEUTICS MARKET, BY TREATMENT TYPE- MARKET ANALYSIS, 2019 - 2032

  • Antiviral Drugs
  • Monoclonal Antibodies
  • Vaccines

GLOBAL RESPIRATORY SYNCYTIAL VIRUS THERAPEUTICS MARKET, BY DOSAGE FORM- MARKET ANALYSIS, 2019 - 2032

  • Oral
  • Injectable
  • Inhalation

GLOBAL RESPIRATORY SYNCYTIAL VIRUS THERAPEUTICS MARKET, BY AGE GROUP- MARKET ANALYSIS, 2019 - 2032

  • Infants & Young Children
  • Adults
  • Older Adults (65+ years)

GLOBAL RESPIRATORY SYNCYTIAL VIRUS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL- MARKET ANALYSIS, 2019 - 2032

  • Hospitals & Clinics
  • Retail Pharmacies
  • Online Pharmacies

GLOBAL RESPIRATORY SYNCYTIAL VIRUS THERAPEUTICS MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

  • North America
  • U.S.
  • Canada
  • Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • The Netherlands
  • Sweden
  • Russia
  • Poland
  • Rest of Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Australia
  • Indonesia
  • Thailand
  • Philippines
  • Rest of APAC
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Rest of LATAM
  • The Middle East and Africa
  • Saudi Arabia
  • UAE
  • Israel
  • Turkey
  • Algeria
  • Egypt
  • Rest of MEA

Table of Contents

1. Respiratory Syncytial Virus Therapeutics Market Overview

  • 1.1. Study Scope
  • 1.2. Market Estimation Years

2. Executive Summary

  • 2.1. Market Snippet
    • 2.1.1. Respiratory Syncytial Virus Therapeutics Market Snippet by Treatment Type
    • 2.1.2. Respiratory Syncytial Virus Therapeutics Market Snippet by Dosage Form
    • 2.1.3. Respiratory Syncytial Virus Therapeutics Market Snippet by Age Group
    • 2.1.4. Respiratory Syncytial Virus Therapeutics Market Snippet by Distribution Channel
    • 2.1.5. Respiratory Syncytial Virus Therapeutics Market Snippet by Country
    • 2.1.6. Respiratory Syncytial Virus Therapeutics Market Snippet by Region
  • 2.2. Competitive Insights

3. Respiratory Syncytial Virus Therapeutics Key Market Trends

  • 3.1. Respiratory Syncytial Virus Therapeutics Market Drivers
    • 3.1.1. Impact Analysis of Market Drivers
  • 3.2. Respiratory Syncytial Virus Therapeutics Market Restraints
    • 3.2.1. Impact Analysis of Market Restraints
  • 3.3. Respiratory Syncytial Virus Therapeutics Market Opportunities
  • 3.4. Respiratory Syncytial Virus Therapeutics Market Future Trends

4. Respiratory Syncytial Virus Therapeutics Industry Study

  • 4.1. PEST Analysis
  • 4.2. Porter's Five Forces Analysis
  • 4.3. Growth Prospect Mapping
  • 4.4. Regulatory Framework Analysis

5. Respiratory Syncytial Virus Therapeutics Market: Impact of Escalating Geopolitical Tensions

  • 5.1. Impact of COVID-19 Pandemic
  • 5.2. Impact of Russia-Ukraine War
  • 5.3. Impact of Middle East Conflicts

6. Respiratory Syncytial Virus Therapeutics Market Landscape

  • 6.1. Respiratory Syncytial Virus Therapeutics Market Share Analysis, 2024
  • 6.2. Breakdown Data, by Key Manufacturer
    • 6.2.1. Established Players' Analysis
    • 6.2.2. Emerging Players' Analysis

7. Respiratory Syncytial Virus Therapeutics Market - By Treatment Type

  • 7.1. Overview
    • 7.1.1. Segment Share Analysis, By Treatment Type, 2024 & 2032 (%)
    • 7.1.2. Antiviral Drugs
    • 7.1.3. Monoclonal Antibodies
    • 7.1.4. Vaccines

8. Respiratory Syncytial Virus Therapeutics Market - By Dosage Form

  • 8.1. Overview
    • 8.1.1. Segment Share Analysis, By Dosage Form, 2024 & 2032 (%)
    • 8.1.2. Oral
    • 8.1.3. Injectable
    • 8.1.4. Inhalation

9. Respiratory Syncytial Virus Therapeutics Market - By Age Group

  • 9.1. Overview
    • 9.1.1. Segment Share Analysis, By Age Group, 2024 & 2032 (%)
    • 9.1.2. Infants & Young Children
    • 9.1.3. Adults
    • 9.1.4. Older Adults (65+ years)

10. Respiratory Syncytial Virus Therapeutics Market - By Distribution Channel

  • 10.1. Overview
    • 10.1.1. Segment Share Analysis, By Distribution Channel, 2024 & 2032 (%)
    • 10.1.2. Hospitals & Clinics
    • 10.1.3. Retail Pharmacies
    • 10.1.4. Online Pharmacies

11. Respiratory Syncytial Virus Therapeutics Market- By Geography

  • 11.1. Introduction
    • 11.1.1. Segment Share Analysis, By Geography, 2024 & 2032 (%)
  • 11.2. North America
    • 11.2.1. Overview
    • 11.2.2. Respiratory Syncytial Virus Therapeutics Key Manufacturers in North America
    • 11.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.2.4. North America Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
    • 11.2.5. North America Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
    • 11.2.6. North America Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
    • 11.2.7. North America Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.2.8. The U.S.
      • 11.2.8.1. Overview
      • 11.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.2.8.3. U.S. Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 11.2.8.4. U.S. Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 11.2.8.5. U.S. Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
      • 11.2.8.6. U.S. Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.2.9. Canada
      • 11.2.9.1. Overview
      • 11.2.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.2.9.3. Canada Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 11.2.9.4. Canada Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 11.2.9.5. Canada Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
      • 11.2.9.6. Canada Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 11.3. Europe
    • 11.3.1. Overview
    • 11.3.2. Respiratory Syncytial Virus Therapeutics Key Manufacturers in Europe
    • 11.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.3.4. Europe Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
    • 11.3.5. Europe Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
    • 11.3.6. Europe Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
    • 11.3.7. Europe Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.3.8. Germany
      • 11.3.8.1. Overview
      • 11.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.8.3. Germany Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 11.3.8.4. Germany Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 11.3.8.5. Germany Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
      • 11.3.8.6. Germany Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.3.9. UK
      • 11.3.9.1. Overview
      • 11.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.9.3. UK Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 11.3.9.4. UK Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 11.3.9.5. UK Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
      • 11.3.9.6. UK Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.3.10. France
      • 11.3.10.1. Overview
      • 11.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.10.3. France Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 11.3.10.4. France Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 11.3.10.5. France Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
      • 11.3.10.6. France Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.3.11. Italy
      • 11.3.11.1. Overview
      • 11.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.11.3. Italy Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 11.3.11.4. Italy Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 11.3.11.5. Italy Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
      • 11.3.11.6. Italy Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.3.12. Spain
      • 11.3.12.1. Overview
      • 11.3.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.12.3. Spain Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 11.3.12.4. Spain Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 11.3.12.5. Spain Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
      • 11.3.12.6. Spain Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.3.13. The Netherlands
      • 11.3.13.1. Overview
      • 11.3.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.13.3. The Netherlands Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 11.3.13.4. The Netherlands Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 11.3.13.5. The Netherlands Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
      • 11.3.13.6. The Netherlands Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.3.14. Sweden
      • 11.3.14.1. Overview
      • 11.3.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.14.3. Sweden Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 11.3.14.4. Sweden Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 11.3.14.5. Sweden Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
      • 11.3.14.6. Sweden Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.3.15. Russia
      • 11.3.15.1. Overview
      • 11.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.15.3. Russia Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 11.3.15.4. Russia Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 11.3.15.5. Russia Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
      • 11.3.15.6. Russia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.3.16. Poland
      • 11.3.16.1. Overview
      • 11.3.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.16.3. Poland Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 11.3.16.4. Poland Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 11.3.16.5. Poland Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
      • 11.3.16.6. Poland Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.3.17. Rest of Europe
      • 11.3.17.1. Overview
      • 11.3.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.17.3. Rest of the Europe Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 11.3.17.4. Rest of the Europe Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 11.3.17.5. Rest of the Europe Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
      • 11.3.17.6. Rest of the Europe Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 11.4. Asia Pacific (APAC)
    • 11.4.1. Overview
    • 11.4.2. Respiratory Syncytial Virus Therapeutics Key Manufacturers in Asia Pacific
    • 11.4.3. APAC Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.4.4. APAC Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
    • 11.4.5. APAC Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
    • 11.4.6. APAC Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
    • 11.4.7. APAC Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.4.8. China
      • 11.4.8.1. Overview
      • 11.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.8.3. China Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 11.4.8.4. China Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 11.4.8.5. China Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
      • 11.4.8.6. China Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.4.9. India
      • 11.4.9.1. Overview
      • 11.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.9.3. India Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 11.4.9.4. India Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 11.4.9.5. India Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
      • 11.4.9.6. India Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.4.10. Japan
      • 11.4.10.1. Overview
      • 11.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.10.3. Japan Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 11.4.10.4. Japan Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 11.4.10.5. Japan Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
      • 11.4.10.6. Japan Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.4.11. South Korea
      • 11.4.11.1. Overview
      • 11.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.11.3. South Korea Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 11.4.11.4. South Korea Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 11.4.11.5. South Korea Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
      • 11.4.11.6. South Korea Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.4.12. Australia
      • 11.4.12.1. Overview
      • 11.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.12.3. Australia Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 11.4.12.4. Australia Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 11.4.12.5. Australia Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
      • 11.4.12.6. Australia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.4.13. Indonesia
      • 11.4.13.1. Overview
      • 11.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.13.3. Indonesia Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 11.4.13.4. Indonesia Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 11.4.13.5. Indonesia Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
      • 11.4.13.6. Indonesia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.4.14. Thailand
      • 11.4.14.1. Overview
      • 11.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.14.3. Thailand Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 11.4.14.4. Thailand Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 11.4.14.5. Thailand Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
      • 11.4.14.6. Thailand Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.4.15. Philippines
      • 11.4.15.1. Overview
      • 11.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.15.3. Philippines Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 11.4.15.4. Philippines Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 11.4.15.5. Philippines Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
      • 11.4.15.6. Philippines Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.4.16. Rest of APAC
      • 11.4.16.1. Overview
      • 11.4.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.16.3. Rest of APAC Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 11.4.16.4. Rest of APAC Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 11.4.16.5. Rest of APAC Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
      • 11.4.16.6. Rest of APAC Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 11.5. Latin America (LATAM)
    • 11.5.1. Overview
    • 11.5.2. Respiratory Syncytial Virus Therapeutics Key Manufacturers in Latin America
    • 11.5.3. LATAM Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.5.4. LATAM Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
    • 11.5.5. LATAM Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
    • 11.5.6. LATAM Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
    • 11.5.7. LATAM Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.5.8. Brazil
      • 11.5.8.1. Overview
      • 11.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.8.3. Brazil Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 11.5.8.4. Brazil Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 11.5.8.5. Brazil Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
      • 11.5.8.6. Brazil Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.5.9. Mexico
      • 11.5.9.1. Overview
      • 11.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.9.3. Mexico Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 11.5.9.4. Mexico Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 11.5.9.5. Mexico Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
      • 11.5.9.6. Mexico Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.5.10. Argentina
      • 11.5.10.1. Overview
      • 11.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.10.3. Argentina Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 11.5.10.4. Argentina Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 11.5.10.5. Argentina Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
      • 11.5.10.6. Argentina Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.5.11. Colombia
      • 11.5.11.1. Overview
      • 11.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.11.3. Colombia Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 11.5.11.4. Colombia Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 11.5.11.5. Colombia Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
      • 11.5.11.6. Colombia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.5.12. Rest of LATAM
      • 11.5.12.1. Overview
      • 11.5.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.12.3. Rest of LATAM Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 11.5.12.4. Rest of LATAM Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 11.5.12.5. Rest of LATAM Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
      • 11.5.12.6. Rest of LATAM Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 11.6. Middle East and Africa (MEA)
    • 11.6.1. Overview
    • 11.6.2. Respiratory Syncytial Virus Therapeutics Key Manufacturers in Middle East and Africa
    • 11.6.3. MEA Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.6.4. MEA Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
    • 11.6.5. MEA Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
    • 11.6.6. MEA Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
    • 11.6.7. MEA Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.6.8. Saudi Arabia
      • 11.6.8.1. Overview
      • 11.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.8.3. Saudi Arabia Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 11.6.8.4. Saudi Arabia Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 11.6.8.5. Saudi Arabia Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
      • 11.6.8.6. Saudi Arabia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.6.9. United Arab Emirates
      • 11.6.9.1. Overview
      • 11.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.9.3. United Arab Emirates Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 11.6.9.4. United Arab Emirates Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 11.6.9.5. United Arab Emirates Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
      • 11.6.9.6. United Arab Emirates Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.6.10. Israel
      • 11.6.10.1. Overview
      • 11.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.10.3. Israel Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 11.6.10.4. Israel Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 11.6.10.5. Israel Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
      • 11.6.10.6. Israel Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.6.11. Turkey
      • 11.6.11.1. Overview
      • 11.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.11.3. Turkey Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 11.6.11.4. Turkey Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 11.6.11.5. Turkey Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
      • 11.6.11.6. Turkey Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.6.12. Algeria
      • 11.6.12.1. Overview
      • 11.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.12.3. Algeria Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 11.6.12.4. Algeria Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 11.6.12.5. Algeria Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
      • 11.6.12.6. Algeria Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.6.13. Egypt
      • 11.6.13.1. Overview
      • 11.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.13.3. Egypt Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 11.6.13.4. Egypt Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 11.6.13.5. Egypt Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
      • 11.6.13.6. Egypt Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.6.14. Rest of MEA
      • 11.6.14.1. Overview
      • 11.6.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.14.3. Rest of MEA Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 11.6.14.4. Rest of MEA Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 11.6.14.5. Rest of MEA Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
      • 11.6.14.6. Rest of MEA Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)

12. Key Vendor Analysis- Respiratory Syncytial Virus Therapeutics Industry

  • 12.1. Competitive Dashboard
    • 12.1.1. Competitive Benchmarking
    • 12.1.2. Competitive Positioning
  • 12.2. Company Profiles
    • 12.2.1. AstraZeneca plc
    • 12.2.2. Sanofi S.A.
    • 12.2.3. Pfizer Inc.
    • 12.2.4. Moderna, Inc.
    • 12.2.5. GSK plc
    • 12.2.6. Merck & Co., Inc.
    • 12.2.7. Johnson & Johnson
    • 12.2.8. Novavax, Inc.
    • 12.2.9. Bavarian Nordic A/S
    • 12.2.10. Enanta Pharmaceuticals, Inc.
    • 12.2.11. BioNTech SE
    • 12.2.12. Meissa Vaccines, Inc.
    • 12.2.13. Codagenix, Inc.
    • 12.2.14. Alnylam Pharmaceuticals, Inc.
    • 12.2.15. Vaxart, Inc.
    • 12.2.16. Icosavax, Inc.

13. 360 Degree AnalystView

14. Appendix

  • 14.1. Research Methodology
  • 14.2. References
  • 14.3. Abbreviations
  • 14.4. Disclaimer
  • 14.5. Contact Us